share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰製藥 | 144:擬議出售證券
美股SEC公告 ·  07/30 15:31
Moomoo AI 已提取核心訊息
Vertex Pharmaceuticals Inc. officer and director, Kewalramani Reshma, is set to sell 15,202 shares of common stock on July 30, 2024, with an aggregate market value of approximately $7,677,010. The shares to be sold were acquired through restricted stock vesting as part of compensation from the issuer on various dates ranging from February 17, 2023, to February 24, 2024. The total number of shares acquired through these transactions amounted to 12,202. This planned sale follows a review of securities sold in the past three months, where a total of 31,969 shares were sold for gross proceeds of $15,065,893. The notice of the upcoming sale was filed on the same date as the planned sale, with the plan for the transaction having been adopted on February 7, 2024.
Vertex Pharmaceuticals Inc. officer and director, Kewalramani Reshma, is set to sell 15,202 shares of common stock on July 30, 2024, with an aggregate market value of approximately $7,677,010. The shares to be sold were acquired through restricted stock vesting as part of compensation from the issuer on various dates ranging from February 17, 2023, to February 24, 2024. The total number of shares acquired through these transactions amounted to 12,202. This planned sale follows a review of securities sold in the past three months, where a total of 31,969 shares were sold for gross proceeds of $15,065,893. The notice of the upcoming sale was filed on the same date as the planned sale, with the plan for the transaction having been adopted on February 7, 2024.
Vertex Pharmaceuticals Inc.董事兼高級職員Kewalramani Reshma計劃在2024年7月30日出售15,202股普通股,合計市值約爲7,677,010美元。這些股票是作爲補償的一部分,在2023年2月17日至2024年2月24日期間,由該公司股票禁售期到期後獲得的。通過這些交易獲得的股票總數爲12,202。這項計劃出售是在審查了過去3個月出售的證券後,所做出的決定,過去3個月共出售31,969股,獲得15,065,893美元的總收益。計劃銷售的通知與計劃銷售的日期相同,交易計劃已於2024年2月7日通過。
Vertex Pharmaceuticals Inc.董事兼高級職員Kewalramani Reshma計劃在2024年7月30日出售15,202股普通股,合計市值約爲7,677,010美元。這些股票是作爲補償的一部分,在2023年2月17日至2024年2月24日期間,由該公司股票禁售期到期後獲得的。通過這些交易獲得的股票總數爲12,202。這項計劃出售是在審查了過去3個月出售的證券後,所做出的決定,過去3個月共出售31,969股,獲得15,065,893美元的總收益。計劃銷售的通知與計劃銷售的日期相同,交易計劃已於2024年2月7日通過。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息